Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

PURPOSE: The study evaluated safety and efficacy of olaratumab + pembrolizumab in patients with unresectable locally advanced/metastatic soft-tissue sarcoma (STS) with disease progression on standard treatment. PATIENTS AND METHODS: This was open-label, multicenter, nonrandomized, phase Ia/Ib dose-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöffski, Patrick, Bahleda, Rastislav, Wagner, Andrew J., Burgess, Melissa A., Junker, Niels, Chisamore, Michael, Peterson, Patrick, Szpurka, Anna M., Ceccarelli, Matteo, Tap, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472093/
https://www.ncbi.nlm.nih.gov/pubmed/37382656
http://dx.doi.org/10.1158/1078-0432.CCR-23-0742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472093/
https://www.ncbi.nlm.nih.gov/pubmed/37382656
http://dx.doi.org/10.1158/1078-0432.CCR-23-0742

Ejemplares similares